Analysis of drugs-based treatment methods for Alzheimer’s disease

Authors

  • Jiayi Li

DOI:

https://doi.org/10.62051/nfe94t51

Keywords:

Alzheimer’s disease; Drugs; Treatment methods.

Abstract

Alzheimer’s disease (AD) treatment is one of the focuses of current medical research. Researchers have made progress in exploring the pathogenesis and treatment for AD, especially with disease-modifying therapies, cognitive enhancers, and medications for neuropsychiatric symptoms. However, there is still a research gap on how to effectively combine these drugs to improve the quality of life for AD patients. Therefore, this research aims to explore the effects of three drugs on AD, including lecanemab, brexpiprazole, and donepezil. This research systematically analyzed the efficacy of three drugs in different aspects of the disease: lecanemab as a disease-modifying therapy, brexpiprazole for relieving agitated symptoms, and donepezil for improving cognitive function. Through the analysis of their action mechanisms and clinical trial data, this research reveals the different roles of these drugs in AD treatment. The research results indicate that the combination of these three drugs can improve patients' symptoms from different aspects. Because of the various pathological mechanisms of AD, individualized multi-drug combination therapy may be an effective direction for future treatment.

Downloads

Download data is not yet available.

References

[1] P. Scheltens, B. De Strooper, M. Kivipelto, et al. Alzheimer's disease, The Lancet 397(10284) (2021) 1577 - 1590.

[2] C. H. Van Dyck, C. J. Swanson, P. Aisen, et al. Lecanemab in early Alzheimer’s disease, New England Journal of Medicine 388 (1) (2023) 9 - 21.

[3] E. McDade, J. L. Cummings, S. Dhadda, et al. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study, Alzheimer's research & therapy 14 (1) (2022) 191.

[4] G. T. Grossberg, E. Kohegyi, V. Mergel, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials, The American Journal of Geriatric Psychiatry 28 (4) (2020) 383 - 400.

[5] R. Howard, R. McShane, J. Lindesay, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease, New England Journal of Medicine 366 (10) (2012) 893 - 903.

[6] J. Jia, C. Wei, W. Chen, et al. Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer’s Disease, Journal of Alzheimer's Disease 74 (1) (2020) 199 - 211.

[7] S. Chowdhury, N. S. Chowdhury Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: a systematic review, international journal of immunopathology and pharmacology 37 (2023) 03946320231209839.

[8] K. Maeda, H. Sugino, H. Akazawa, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator, Journal of pharmacology and experimental therapeutics 350 (3) (2014) 589 - 604.

[9] B. Seltzer Donepezil: a review, Expert opinion on drug metabolism & toxicology 1 (3) (2005) 527 - 536.

Downloads

Published

24-12-2024

How to Cite

Li, J. (2024). Analysis of drugs-based treatment methods for Alzheimer’s disease. Transactions on Materials, Biotechnology and Life Sciences, 7, 591-596. https://doi.org/10.62051/nfe94t51